SRNE (Sorrento Therapeutics) DeferredTaxAndRevenue: $0.26 Mil (As of Jun. 2023)


SRNE Sorrento Therapeutics Inc SRNE
12 GF Score
Price $0.00
View Full Analysis

What is Sorrento Therapeutics DeferredTaxAndRevenue?

Sorrento Therapeutics SRNE 12 DeferredTaxAndRevenue is $0.26 Mil as of Jun. 2023. GuruFocus rates SRNE with a GF Score™ of 12/100.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Sorrento Therapeutics's current deferred tax and revenue for the quarter that ended in Jun. 2023 was $0.26 Mil.

Sorrento Therapeutics DeferredTaxAndRevenue Related Terms

Sorrento Therapeutics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Sorrento Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics DeferredTaxAndRevenue Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.70 3.64 4.49 1.11 0.65

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.02 0.28 0.65 0.25 0.26
SRNE
12GF Score
Sorrento Therapeutics Inc SRNE
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.26 Mil mean?
Sorrento Therapeutics (SRNE) has a DeferredTaxAndRevenue of $0.26 Mil as of Jun. 2023. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Sorrento Therapeutics.
Is Sorrento Therapeutics' DeferredTaxAndRevenue too high?
Sorrento Therapeutics' current DeferredTaxAndRevenue is $0.26 Mil. Overall, Sorrento Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sorrento Therapeutics' DeferredTaxAndRevenue compare to IMUX and OCUP?
Sorrento Therapeutics' DeferredTaxAndRevenue of $0.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Sorrento Therapeutics. Sorrento Therapeutics's current DeferredTaxAndRevenue is $0.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sorrento Therapeutics stock overvalued right now?
Sorrento Therapeutics (SRNE) has a current DeferredTaxAndRevenue of $0.26 Mil. The current DeferredTaxAndRevenue is $0.26 Mil. Sorrento Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Sorrento Therapeutics (SRNE), the current DeferredTaxAndRevenue is $0.26 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sorrento Therapeutics Business Description

Address 4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
12GF Score

Get the complete analysis for SRNE

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price